Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Public HealthIssue 614

BPA's Diabetes Link Strengthened by New Study

Growing evidence suggests that even minuscule amounts of BPA (used in everything from pesticides to water bottles) can scramble hormone signals, and trick fat cells into taking in more fat or mislead the pancreas into secreting excess insulin....

Advertisement

Among the most ubiquitous and scrutinized of these so-called endocrine disruptors is bisphenol, better known as BPA. The chemical is a common ingredient in plastics and food-can linings.

Angel Nadal, a BPA expert at the Miguel Hernandez University in Spain stated that, "When you eat something with BPA, it's like telling your organs that you are eating more than you are really eating."

Nadal's latest research, finds that the chemical triggers the release of almost double the insulin actually needed to break down food. High insulin levels can desensitize the body to the hormone over time, which in some people may then lead to weight gain and Type 2 diabetes.

To achieve this feat, BPA fools a receptor into thinking it is the natural hormone estrogen, an insulin regulator. Nadal's team found that even the tiniest amounts of BPA -- a quarter of a billionth of a gram -- did the trick. The effect disappeared when the researchers stripped the specific receptors from the study mice, evidence that they had in fact pinpointed BPA's chemical mechanism, which had previously eluded scientists. In laboratory tests of human cells, the response was even more pronounced.

"That pretty much nails it," Bruce Blumberg of the University of California, Irvine, who was not involved in the new study, told The Huffington Post. He notes that despite the prior associations made between BPA and metabolic problems, including obesity and diabetes, doubt had lingered because of a lack of understanding about how the phenomenon occurred. Long-term studies of children -- tracking BPA exposures and health outcomes -- remain ongoing around the world.

An estimated 90 percent of people in developed countries have BPA circulating in their blood at levels often higher than the threshold for causing hormone disruption used in Nadal's study. This high incidence is due not only to exposures from leaching food packages but also BPA-infused cash register receipts, dental sealants and toilet paper.

Frederick vom Saal, another expert in endocrine disruptors at the University of Missouri-Columbia stated that, "People are seeing effects of BPA down to 1000-fold below [Nadal's threshold]." "It takes so little of this chemical to cause harm."

Published in PLoS ONE, Feb 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 21 February, 2012 and appeared in  Public HealthIssue 614

Past five issues: Issue 766 | Diabetes Clinical Mastery Series Issue 225 | Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 |

2015 Most Popular Articles:

Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
New Guideline Released on Pharmacological Management of Obesity
Posted January 23, 2015
For Your Patients: Practical Advice to Rev Up Your Workouts and Lower Fatigue
Posted January 09, 2015
Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Posted January 12, 2015
Phentermine and Topirimate ER (Qsymia) Studied for Type 2 Diabetes Patients
Posted January 15, 2015
Handbook of Diabetes, 4th Ed., Excerpt #25: Specific Circumstances that Affect Diabetes Control
Posted January 04, 2015
New Insulin Glargine 300 Effective in Type 1 Diabetes
Posted January 16, 2015
FDA Approves Maestro Electronic Weight Loss Device
Posted January 23, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
CME/CE of the Week
Joy Pape, RN, BSN, DE, WOCN, CPT 

Category: Nursing
Credits: .75


Advertisement


Search Articles On Diabetes In Control